Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice
In this study, we examined the in-vivo characteristics of a novel microencapsulated thalidomide formulation in a murine model of experimental Crohn's disease. Crohn's disease was induced with a single intra-colonic injection of 120 mg/kg of bodyweight of 2,5,6-trinitrobenzene sulfonic acid...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Bentham Science Publishers
2014
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/20167 |
| _version_ | 1848750232209195008 |
|---|---|
| author | Fakhoury, M. Coussa-Charley, M. Al-Salami, Hani Kahouli, I. Prakash, S. |
| author_facet | Fakhoury, M. Coussa-Charley, M. Al-Salami, Hani Kahouli, I. Prakash, S. |
| author_sort | Fakhoury, M. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | In this study, we examined the in-vivo characteristics of a novel microencapsulated thalidomide formulation in a murine model of experimental Crohn's disease. Crohn's disease was induced with a single intra-colonic injection of 120 mg/kg of bodyweight of 2,5,6-trinitrobenzene sulfonic acid (TNBS) dissolved in 30% ethanol in Balb/c mice. Level of tumor necrosis factor alpha (TNF-), interleukin one beta (IL-1), interleukin 6 (IL-6) and nitric oxide (NO) were measured in tissue homogenate. Moreover, myeloperoxidase (MPO) activity was determined to assess the extent of neutrophil infiltration. Dose response study showed that treating the mice with microencapsulated thalidomide (100 mg/kg of bodyweight) for two weeks significantly decreased the degree of intestinal inflammation related to Crohn’s disease. Higher and lower doses (0, 25, 50 and 200 mg/kg of bodyweight) did not exhibit comparable effects. The present study validates the success of alginate-poly-L-lysine-alginate (APA) microcapsules containing thalidomide in reducing colonic inflammation, and proposes a potential remedy for Crohn’s disease. |
| first_indexed | 2025-11-14T07:33:33Z |
| format | Journal Article |
| id | curtin-20.500.11937-20167 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T07:33:33Z |
| publishDate | 2014 |
| publisher | Bentham Science Publishers |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-201672017-09-13T13:51:03Z Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice Fakhoury, M. Coussa-Charley, M. Al-Salami, Hani Kahouli, I. Prakash, S. molecular markers Crohn’s disease APA microcapsules in vivo study thalidomide In this study, we examined the in-vivo characteristics of a novel microencapsulated thalidomide formulation in a murine model of experimental Crohn's disease. Crohn's disease was induced with a single intra-colonic injection of 120 mg/kg of bodyweight of 2,5,6-trinitrobenzene sulfonic acid (TNBS) dissolved in 30% ethanol in Balb/c mice. Level of tumor necrosis factor alpha (TNF-), interleukin one beta (IL-1), interleukin 6 (IL-6) and nitric oxide (NO) were measured in tissue homogenate. Moreover, myeloperoxidase (MPO) activity was determined to assess the extent of neutrophil infiltration. Dose response study showed that treating the mice with microencapsulated thalidomide (100 mg/kg of bodyweight) for two weeks significantly decreased the degree of intestinal inflammation related to Crohn’s disease. Higher and lower doses (0, 25, 50 and 200 mg/kg of bodyweight) did not exhibit comparable effects. The present study validates the success of alginate-poly-L-lysine-alginate (APA) microcapsules containing thalidomide in reducing colonic inflammation, and proposes a potential remedy for Crohn’s disease. 2014 Journal Article http://hdl.handle.net/20.500.11937/20167 10.2174/156720181101140212170025 Bentham Science Publishers restricted |
| spellingShingle | molecular markers Crohn’s disease APA microcapsules in vivo study thalidomide Fakhoury, M. Coussa-Charley, M. Al-Salami, Hani Kahouli, I. Prakash, S. Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice |
| title | Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice |
| title_full | Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice |
| title_fullStr | Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice |
| title_full_unstemmed | Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice |
| title_short | Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice |
| title_sort | use of artificial cell microcapsule containing thalidomide for treating tnbs-induced crohn's disease in mice |
| topic | molecular markers Crohn’s disease APA microcapsules in vivo study thalidomide |
| url | http://hdl.handle.net/20.500.11937/20167 |